Variant

Dear reader, in February 2025, a baby in Philadelphia named KJ received the first of three doses of a medicine that had never existed before and will never be given to anyone else. He was born with a severe deficiency of an enzyme called CPS1, which meant his body could not process the protein in ordinary food, and the ammonia accumulating in his blood was likely to damage his brain and then kill him. A team at the Children's Hospital of Philadelphia and Penn read his two CPS1 variants and developed a base-editing therapy targeting one of them. Six months from diagnosis to infusion. A year on, he was walking and meeting his milestones on a diet his diagnosis was never meant to allow, though his long-term prognosis is still unknown.

That is a moving story, and it would have remained just a story had the regulator not acted on it. In February this year, the American FDA published draft guidance for what it calls a plausible mechanism framework, a way of assembling evidence for individualized genetic therapies, first sketched by its leadership in the New England Journal of Medicine last November. Its logic rests on a technical fact: in CRISPR therapy, the editing protein and the delivery vehicle remain the same from patient to patient, while only a short guide sequence changes. So the agency proposes to authorize the platform rather than the product, allowing a single trial to cover many patients each receiving their own edit, provided the cause is understood at the genetic level, and the therapy demonstrably targets it. Britain's regulator has gone further: the MHRA's draft rare disease therapies framework, out for consultation until the end of this month, would allow a single marketing authorization to cover many patient-specific variants of one validated process.

Every commentary I have read treats this as a rare disease story. In Saudi Arabia, it is not a rare disease story. It is a national one.

Estimates of consanguinity here cluster around 50-60 percent of marriages, with 56 percent the most-cited figure, and first cousins the largest single category. The genetic consequence is not controversial: when both parents carry the same recessive variant, conditions that are vanishingly uncommon elsewhere become recurrent here, concentrated in particular families, regions, and tribes. The Catalog for Transmission Genetics in Arabs records a higher proportion of recessive disorders in Saudi Arabia than in any other Arab country, with 50 to 60 percent of the conditions it lists for us. And in one Saudi tertiary hospital series, exome sequencing yielded a diagnosis in about 42 percent of patients tested, well above the yield usually reported in Western cohorts, for the straightforward reason that answers are easier to find when the same variant arises on both sides of a family.

Which means we have already done the expensive half of the work. The Saudi Human Genome Program has been cataloging our variants since 2013. The premarital screening program has been running since 2004, though it tests a narrow panel, sickle cell and thalassemia, rather than the genome. We know, better than most countries know about themselves, what we carry.

What we have never built is the bridge from a variant to a therapy. Screening prevents, and prevention is worth a great deal, but it does nothing for the child already in the ward, and every year it produces families holding a precise molecular diagnosis and nothing to do with it. Three things would change that, and none requires a scientific breakthrough. A national rare disease registry that links each diagnosis to whether the variant is editable. Manufacturing capacity for small batches of genetic medicine is the real bottleneck and the least glamorous item on the list. And an explicit position from our regulator on whether it will authorize a platform or demand a fresh file for every child, because that single decision determines whether any of this is possible here at all.

I would be dishonest to present the pathway as settled. Approving a plausible mechanism rather than a demonstrated outcome is a genuine loosening; ethicists have warned that it may prove difficult to close again, and there is an awkward irony in the same American center launching a flexible route for individualized therapies while rejecting several conventional rare disease products. More to the point for us, both officials who designed the framework left the agency within months of announcing it, the center director at the end of April, and the commissioner in May. Nor is regulation the only barrier: a bespoke edit costs on the order of a million dollars a child, and no health system in the world has yet decided who pays for a medicine with one patient. Another country's regulatory enthusiasm is a poor foundation for a national strategy. Build the capability, not the dependency.

Dear reader, for fifty years, the only serious thing medicine could offer a family carrying the same variant twice was advice about whom their children should marry. That is prevention, and it arrives too late for the patient already here. For the first time, there is a plausible route to treating the individual child rather than counseling the next generation. No country on earth has more reason to take that route seriously than this one, and few with our resources are moving more slowly.